Study ID: FSS-AS-40139

Study Title

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Patients 13 Years or Older With Asthma

Teva Identifier

FSS-AS-40139 Identifier


Study Status


Trial Condition(s)



Drug: Fluticasone propionate/salmeterol (FS) | Drug: Albuterol | Drug: Standard of Care Asthma Medication | Drug: Standard of Care Rescue Medication

Study Description

The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) compared to the Standard of Care (SoC) group.

The secondary objective is to describe the asthma management actions by investigational center health care providers (iHCPs) for Female, Male participants in both groups, to evaluate short-acting beta2 agonist (SABA) usage and the number of SABA-free days in the DS group, to evaluate adherence patterns to maintenance treatment (FS eMDPI) in the DS group, to assess behavioral correlates of responsiveness to digital health technology among patients for Female, Male participants in both groups, to evaluate work productivity and activity impairment in asthma patients in both groups, to assess the usability and acceptability of the DS by patients in the DS group and the investigational center personnel, and to evaluate the safety of FS eMDPI and Albuterol eMDPI.

Key Participation Requirements


Female, Male

Age Range

13 Years and older

Trial Duration

February 16, 2021 - March 4, 2022


Phase 4

Additional info

Study Type